DMAC Nasdaq

DiaMedica Therapeutics Inc.

DMAC | $2.42 -3.59% 5.53% 5.2K

(0.0% 1d) (-9.7% 1m) (58.2% 1y) (0.0% 2d) (-3.6% 3d) (1.3% 7d) (-75.24% volume)
Earnings Calendar: 2024-03-26
Market Cap: $ 91,858,360
http://www.diamedica.com
Sec Filling | Patents | 9 employees

DiaMedica Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It offers DM199 product which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.

kidney diseases kidney

add to watch list Paper trade email alert is off

Press-releases

DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
Published: 2024-04-17 (Crawled : 22:00) - biospace.com/
DMAC | $2.42 -3.59% 5.53% 5.2K

Health Technology

| 2.11% | O: 4.43% H: 0.0% C: 0.0%
dm199 first stroke treatment for trial therapeutics

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
Published: 2024-03-19 (Crawled : 21:00) - biospace.com/
NKTR | News | $1.42 4.41% 3.89% 1.1M

Health Technology

| 62.94% | O: -2.12% H: 9.21% C: 4.35%
MRNS | $1.44 -2.37% -1.37% 2.6M

Health Technology

| -84.04% | O: -0.22% H: 5.56% C: 3.33%
DMAC | $2.42 -3.59% 5.53% 5.2K

Health Technology

| -15.09% | O: -2.11% H: 4.96% C: 1.08%
business year update therapeutics financial results

DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
Published: 2024-01-22 (Crawled : 14:30) - biospace.com/
NKTR | News | $1.42 4.41% 3.89% 1.1M

Health Technology

| 158.98% | O: -0.9% H: 4.72% C: -3.75%
MRNS | $1.44 -2.37% -1.37% 2.6M

Health Technology

| -85.02% | O: -1.14% H: 6.63% C: 6.53%
DMAC | $2.42 -3.59% 5.53% 5.2K

Health Technology

| -14.18% | O: -0.71% H: 2.14% C: -0.36%
medical therapeutics

DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023
Published: 2023-11-09 (Crawled : 15:00) - biospace.com/
DMAC | $2.42 -3.59% 5.53% 5.2K

Health Technology

| 2.11% | O: -2.95% H: 3.91% C: 2.17%
conference therapeutics

DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023
Published: 2023-11-06 (Crawled : 14:00) - biospace.com/
DMAC | $2.42 -3.59% 5.53% 5.2K

Health Technology

| -4.72% | O: -0.79% H: 6.35% C: 0.0%
report business update therapeutics financial results

DiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth Conference
Published: 2023-09-06 (Crawled : 14:30) - biospace.com/
DMAC | $2.42 -3.59% 5.53% 5.2K

Health Technology

| -27.33% | O: 2.1% H: 0.0% C: -0.59%
conference therapeutics growth

DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023
Published: 2023-08-08 (Crawled : 13:00) - biospace.com/
DMAC | $2.42 -3.59% 5.53% 5.2K

Health Technology

| -18.24% | O: 3.72% H: 2.44% C: 0.65%
report business update therapeutics financial results

DiaMedica Therapeutics to Attend the American Academy of Neurology Summer Conference
Published: 2023-07-18 (Crawled : 14:20) - biospace.com/
DMAC | $2.42 -3.59% 5.53% 5.2K

Health Technology

| -40.83% | O: 0.0% H: 5.87% C: -3.91%
conference therapeutics

DiaMedica Therapeutics Announces Closing of $37.5 Million Private Placement
Published: 2023-06-26 (Crawled : 14:00) - biospace.com/
DMAC | $2.42 -3.59% 5.53% 5.2K

Health Technology

| -43.06% | O: 1.18% H: 10.47% C: 2.33%
therapeutics